Zerotens®

For the treatment of

high blood pressure, hypertension.

Zerotens is a food supplement with natural milk ingredients

Zerotens contains special natural milk ingredients. Zerotens lowers the blood pressure in a natural way when combined with a balanced diet and a healthy lifestyle.

Operational mechanism

The milk ingredients of Zerotens work via the ACE (Angiotension Converting Enzyme) mechanism. The milk ingredients inhibit the ACE in a natural way. Furthermore, this inhibition happens in a mild manner: the active location of the ACE enzyme is not blocked entirely.

The development of high blood pressure is prevented by inhibition of the ACE. High blood pressure is after all caused by the release of Angiotensin II, a process that involves ACE. ACE helps in the conversion of Angiotensin I to Angiotensin II. Angiotensin II causes vasoconstriction. This contraction of the blood vessels causes an increased blood pressure.

With Zerotens, a decrease of the blood pressure is already recorded within the first week. A balance is attained after three weeks.

Galenic form

Zerotens consists of film-coated tablets for swallowing.

Directions for use

The recommended dose amounts to 4 tablets per day. Depending on the circumstances, the recommended dose can be lowered to 2 tablets a day after 3 weeks. It is best to take 1 to 2 tablets in the mornings and 1 to 2 tablets in the evenings, always with meals.

Contraindications and precautions

Zerotens is not recommended for

- pregnant and breastfeeding women,
- children under the age of 5,
- persons with milk protein or lactose allergies.

Side effects - Interactions with medicines

At present neither side effects nor interactions with medicines are known.

Zerotens supports and complements the effect of medication for lowering blood pressure. Patients who take medication for lowering blood pressure, may only use Zerotens under medical supervision.

Latest update: August 2006.

Innoceutics byba

IIC University of Ghent Technologiepark 3 9052 Zwijnaarde Belgium

www.innoceutics.com contact@innoceutics.com

Tel: + 32 (0)9 241 56 00 Fax: + 32 (0)9 241 56 56

References

- Cadée JA et al., A double-blind placebo controlled trial of four weeks administration of C12 Peption effect in Taiwan shows the potential to lower blood pressure form a prehypertensive stage to a normotensive level., Am. J. Hyp. 2006, accepted for publication;
- Townsend RR, McFadden CB, Ford V and Cadée JA, A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate in human essential hypertension, Am. J. Hyp. 2004, 17:1056-1058.